Head and Neck Neoplasm Clinical Trial
Official title:
A Phase I Trial of MR-Guided Dose-Escalated Hypofractionated Adaptive Radiation Therapy and Immunotherapy in Primary Metastatic or Very Locally Advanced Patients With Head and Neck Cancer
Locoregional failure remains the principal mode of mortality in head and neck squamous cell carcinoma (HNSCC) treated with conventional chemoradiation therapy. Magnetic resonance-guided radiation therapy (MRgRT) allows for adaptive radiation dose escalation based on tumor response and may improve therapeutic outcomes while limiting toxicities. This protocol evaluates a novel framework for radiation delivery with concurrent atezolizumab in patients with advanced HNSCC. Dose-Escalated Hypofractionated Adaptive Radiotherapy (DEHART) modifies radiation dose using MRgRT by escalating radiation dose to residual tumor while deescalating radiation dose to areas of tumor regression.
Locoregional failure remains the principal mode of mortality in head and neck squamous cell carcinoma (HNSCC) treated with conventional chemoradiation therapy. Radiation dose escalation with hypofractionation has shown unparalleled local control in other malignancies, such as non-small cell lung cancer, but has been limited in HNSCC due to toxicity concerns. Magnetic resonance-guided radiation therapy (MRgRT) allows for adaptive radiation dose escalation based on tumor response and may improve therapeutic outcomes while limiting toxicities. This protocol evaluates a novel framework for radiation delivery using MRgRT with concurrent atezolizumab in patients with advanced HNSCC. Unlike conventional radiotherapy, Dose-Escalated Hypofractionated Adaptive Radiotherapy (DEHART) modifies radiation dose using MRgRT by adapting the radiation plan during the course of treatment, escalating radiation dose to residual tumor while deescalating radiation dose to areas of tumor regression. The hypothesis is that DEHART will safely deliver ablative radiation doses in 15 fractions over 3 weeks while limiting both toxicity and the effect of tumor repopulation by resistant clonogens, thus resulting in an improved therapeutic ratio. This Phase I clinical trial will encompass the following specific aims: (1) determine the maximum tolerated dose (MTD) of the DEHART regimen delivered using MRgRT with concurrent atezolizumab in a population of patients who are not candidates or unsuitable for definitive chemoradiation therapy; (2) evaluate the toxicity and functional outcomes of the DEHART regimen; and (3) assess the efficacy of DEHART and obtain volumetric and functional imaging correlates of efficacy using MRgRT to serve as hypothesis-generating data for future trials of radiation dose adaptation. A modified Time-to Event Continual Reassessment (TITE-CRM) Phase I Design with three radiation dose levels delivered to regressing disease will be used to determine the MTD: 50 Gy in 15 fractions, 55 Gy in 15 fractions and 60 Gy in 15 fractions. If DEHART is found to be safe and shows a signal of efficacy in this study, a future Phase II trial will be conducted to compare this novel treatment strategy to standard-of care conventionally fractionated chemoradiation in patients with locally advanced HNSCC. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02960308 -
Whole-Neck Computed Tomography Perfusion Scan in Imaging Patients With Head and Neck Tumors
|
||
| Terminated |
NCT02602067 -
131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients
|
Phase 1 | |
| Completed |
NCT04277273 -
Characteristics of a Maxillofacial Prosthesis Consultation Within Assistance Publique - Hopitaux de Paris
|
N/A | |
| Completed |
NCT03896906 -
Preoxygenation With a High-flow Nasal Cannula or a Simple Mask Before General Anesthesia in Head and Neck Surgery
|
N/A | |
| Completed |
NCT01621295 -
Assessing the Patient Experience in Cancer Care
|
N/A | |
| Active, not recruiting |
NCT03854838 -
IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.
|
Phase 2 | |
| Completed |
NCT04151030 -
Endoscopic Direct-PEG Placement in Patients Unable to Undergo Pull-PEG Procedure
|
N/A | |
| Completed |
NCT03012581 -
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
|
Phase 2 | |
| Active, not recruiting |
NCT04005521 -
Randomized Study Regarding Preventive Jaw- and Swallowing Intervention for Patients With Head and Neck Cancer
|
N/A | |
| Recruiting |
NCT05011500 -
Masks Against Surface-Scanning for Radiation Therapy Immobilisation in Head and Neck Cancer (MASSC)
|
N/A | |
| Completed |
NCT05590650 -
A Pilot Study of Additional Chinese Formula for Concurrent Chemoradiotherapy in Oral Cavity Cancer Patients
|
Phase 1 | |
| Terminated |
NCT03402737 -
SBRT + Immunomodulating Systemic Therapy for Inoperable, Recurrent H&N
|
N/A | |
| Completed |
NCT04086849 -
Analysis of Patterns of Recurrence in Head and Neck Cancer Using Clinicopathomic Markers
|
||
| Completed |
NCT00001442 -
A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer
|
Phase 1 | |
| Terminated |
NCT00423150 -
Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)
|
Phase 2 | |
| Recruiting |
NCT03757091 -
Flexible Intubation Scope With or Without Video Laryngoscope in Supporting Endotracheal Tube Placement in Patients With Head and Neck Cancer Before Surgery
|
N/A | |
| Recruiting |
NCT04099290 -
Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma
|
||
| Withdrawn |
NCT04679233 -
Feasibility and Safety of Aerobic Exercise for Head and Neck Cancer Patients
|
N/A | |
| Not yet recruiting |
NCT04267627 -
Telemedicine Nurse-Led Intervention for Rural Cancer Survivors
|
N/A | |
| Completed |
NCT00666926 -
Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms
|
Phase 1 |